Pyxis Oncology reports Q3 net loss of $22 mln

Pyxis Oncology

03/11/2025 12:15

Overview

Pyxis Oncology reports Q3 net loss of $22 mln, consistent with prior year

Company anticipates preliminary data from MICVO Phase 1 studies in Q4 2025

Expected cash runway through data milestones into second half of 2026

Outlook

Pyxis Oncology expects preliminary data from MICVO studies in 4Q25

Company anticipates cash runway into second half of 2026

Pyxis Oncology to announce next steps in MICVO development with data update

Result Drivers

G&A COSTS FALL - The decrease was primarily due to lower corporate insurance costs and a decrease in legal, professional and consulting fees

TRANSLATIONAL INSIGHTS - New data presented at ESMO and AACR-NCI-EORTC highlight MICVO's mechanism of action and potential benefits in tumor microenvironment remodeling

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.35
Q3 Net Income
-$22 mln
Q3 Basic EPS
-$0.35
Q3 Income from Operations
-$23.46 mln


Press Release: ID:nGNX6XTnxk

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)